- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Kebriaei on the Potential Shift Away From Transplant in ALL
September 5th 2024, 7:25pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.
Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma
September 5th 2024, 5:40pm
Society of Hematologic Oncology Annual Meeting (SOHO)
The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.
Imetelstat Delivers Sustained RBC-TI With No OS Detriment in Lower-Risk MDS
September 5th 2024, 5:14pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Imetelstat sustained red blood cell (RBC) transfusion independence in patients with RBC transfusion–dependent lower-risk myelodysplastic syndrome.
Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma
September 5th 2024, 1:00pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.
Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL
September 4th 2024, 9:55pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Dr Smith on Bispecific Antibodies for the Management of R/R Follicular Lymphoma
September 4th 2024, 9:20pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.
Dr Giralt on Determining Transplant Eligibility in MDS
September 4th 2024, 9:12pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.
Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC
August 12th 2024, 8:26pm
Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.
Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia
August 12th 2024, 6:00pm
Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.
Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC
August 12th 2024, 5:07pm
Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.
Sonrotoclax/Zanubrutinib Leads to Durable Responses in R/R CLL/SLL
August 12th 2024, 12:00pm
Stephen Opat, MBBS, discusses data for sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
RPS-Optimized Checkpoint Inhibition Bolsters pCR in Patients With Select Rare Breast Cancers
August 9th 2024, 5:50pm
High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.
Enfortumab Vedotin/Pembrolizumab Does Not Negatively Impact QOL in Metastatic Urothelial Cancer
August 9th 2024, 5:22pm
Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.
CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion
August 8th 2024, 9:09pm
CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.
Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC
August 8th 2024, 8:05pm
Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.
Pacritinib Demonstrates Safety in Solid Tumors Harboring 1q21.3 Amplifications
August 8th 2024, 6:26pm
Pacritinib was tolerable with a reasonable safety profile in patients with solid tumors harboring 1q21.3 copy number amplifications.
Serial Clinical Response Evaluation Aids in Residual Disease Detection in ESCC
August 7th 2024, 3:00pm
Bite-on-bite biopsies and endoscopic ultrasonography with fine needle aspiration were accurate in detecting MRD after neoadjuvant chemoradiotherapy in ESCC.
Selpercatinib Maintains PFS Benefit vs Chemotherapy in East Asian Patients With Untreated RET+ NSCLC
August 7th 2024, 12:00pm
East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.
IMRT Alone is Non-Inferior to CCRT in Nasopharyngeal Carcinoma
August 6th 2024, 5:04pm
Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.
Dr Bazhenova on Improving Biomarker Development in Lung Cancer
August 5th 2024, 2:40pm
Bridging the Gaps in Lung Cancer
Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.